Biosimilar Drug Regulation Cases in Third Circuit

Browse 2 biosimilar drug regulation cases decided by Third Circuit. AI-powered summaries, holdings, and legal analysis.

2
Cases
1
Defendant Win
1
Mixed

Biosimilar Drug Regulation Opinions from Third Circuit (2)

Johnson & Johnson v. Samsung Bioepis Co Ltd

Third Circuit: Biosimilar Renflexis Does Not Infringe Remicade Patents

Third Circuit · 2026-04-14 · Defendant Win · Impact: 75/100

Johnson & Johnson v. Samsung Bioepis Co Ltd, decided by Third Circuit on April 14, 2026, resulted in a defendant win outcome. The Third Circuit affirmed the District Court's grant of summary judgment ...

Amgen Inc v. Celltrion USA Inc

CA3 Affirms Enbrel Patent Infringement, Reverses Willfulness Finding

Third Circuit · 2025-06-05 · Mixed · Impact: 60/100

Amgen Inc v. Celltrion USA Inc, decided by Third Circuit on June 5, 2025, resulted in a mixed outcome. The Third Circuit affirmed the District Court's finding of infringement of Amgen's patents for it...

Frequently Asked Questions

Q: How many biosimilar drug regulation cases has Third Circuit decided?

CaseLawBrief currently tracks 2 biosimilar drug regulation cases from Third Circuit. This number is updated as new opinions are published.

Q: What types of outcomes occur in biosimilar drug regulation cases at Third Circuit?

Outcome breakdown: Defendant Win: 1, Mixed: 1.

Q: Where can I find plain English summaries of biosimilar drug regulation rulings from Third Circuit?

Each case page on CaseLawBrief includes an AI-generated plain English summary, key holdings, and legal analysis. Click any case above to read its full analysis.

Explore More

All Third Circuit Cases All Biosimilar Drug Regulation Cases All Courts All Topics Search